Samad Rastmanesh, Ilghar Zeinaly, Vahid Alivirdiloo, Ahmad Mobed, Mohammad Darvishi
{"title":"Biosensing for rapid detection of MDR, XDR and PDR bacteria.","authors":"Samad Rastmanesh, Ilghar Zeinaly, Vahid Alivirdiloo, Ahmad Mobed, Mohammad Darvishi","doi":"10.1016/j.cca.2024.120121","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria poses a significant threat to global public health, complicating the management of infectious diseases and increasing morbidity and mortality rates. Rapid and sensitive detection of these resistant pathogens is crucial for effective treatment and infection control. This manuscript provides a comprehensive overview of various biosensor technologies developed for the rapid identification and quantification of MDR and XDR bacteria. We discuss the principles of operation, sensitivity, specificity, and practical applications of different biosensing platforms, including electrochemical, optical, and piezoelectric sensors. Additionally, we explore recent advancements in nanomaterials and microfluidics that enhance biosensor performance and enable point-of-care testing. The manuscript also addresses the challenges faced in the implementation of these technologies in clinical settings, such as regulatory hurdles and the need for standardization. A systematic literature review was conducted to identify relevant studies. Databases utilized include PubMed and Scopus, covering the time frame from 2015 to 2024. The literature screening criteria focused on the inclusion of only clinically validated studies to ensure the reliability and applicability of the findings. By highlighting the potential of biosensors to revolutionize the detection of drug-resistant bacteria, this work aims to inform researchers, clinicians, and policymakers about the critical role of innovative diagnostic tools in combating antibiotic resistance and improving patient outcomes.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120121"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2024.120121","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria poses a significant threat to global public health, complicating the management of infectious diseases and increasing morbidity and mortality rates. Rapid and sensitive detection of these resistant pathogens is crucial for effective treatment and infection control. This manuscript provides a comprehensive overview of various biosensor technologies developed for the rapid identification and quantification of MDR and XDR bacteria. We discuss the principles of operation, sensitivity, specificity, and practical applications of different biosensing platforms, including electrochemical, optical, and piezoelectric sensors. Additionally, we explore recent advancements in nanomaterials and microfluidics that enhance biosensor performance and enable point-of-care testing. The manuscript also addresses the challenges faced in the implementation of these technologies in clinical settings, such as regulatory hurdles and the need for standardization. A systematic literature review was conducted to identify relevant studies. Databases utilized include PubMed and Scopus, covering the time frame from 2015 to 2024. The literature screening criteria focused on the inclusion of only clinically validated studies to ensure the reliability and applicability of the findings. By highlighting the potential of biosensors to revolutionize the detection of drug-resistant bacteria, this work aims to inform researchers, clinicians, and policymakers about the critical role of innovative diagnostic tools in combating antibiotic resistance and improving patient outcomes.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.